Capstone Investment Advisors
PLX icon

Capstone Investment Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Capstone Investment Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,336
Closed -$39.3K – 1705
2025
Q1 		$39.3K Buy
+15,336
New +$36.6K ﹤0.01% 1301
2021
Q2 		– Sell
-21,058
Closed -$94K – 1838
2021
Q1 		$94K Sell
21,058
-1,094
-5% -$5.09K ﹤0.01% 1550
2020
Q4 		$80K Buy
+22,152
New +$79.4K ﹤0.01% 1584

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Capstone Investment Advisors's PLX Position: Q2 2025 in Review

Capstone Investment Advisors sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 15,336 shares — an estimated $39.3K sold.

Capstone Investment Advisors first reported a position in PLX in Q4 2020 and held it in 3 quarters. The position peaked at $94K in Q1 2021. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

  • Capstone Investment Advisors reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 15,336 Protalix BioTherapeutics shares in Q2 2025, an estimated $39.3K.
  • Capstone Investment Advisors first reported a position in Protalix BioTherapeutics in Q4 2020 and held it in 3 quarters.
  • Capstone Investment Advisors's Protalix BioTherapeutics position peaked at $94K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on Capstone Investment Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.